Understand Your CHOLESTEROL PANEL & Metabolic Health Tests - The ULTIMATE Guide

Reading Your Cholesterol Panel: What the Numbers Actually Mean

Dr. Robert Lustig, appearing on the Levels channel, delivers a masterclass on understanding your cholesterol panel and metabolic health tests. With 2.2 million views, this video has clearly filled a massive information gap. Most people get their cholesterol results, glance at the numbers, and have no idea what any of it means beyond "high is bad." Dr. Lustig dismantles that oversimplification and explains what each number actually tells you about your metabolic health, cardiovascular risk, and overall disease trajectory. For anyone on GLP-1 medications, understanding these numbers is particularly important because these drugs change your metabolic profile in ways that should show up on your lab work.

Dr. Lustig starts with the basics: total cholesterol, LDL, HDL, and triglycerides. But he quickly moves beyond the headline numbers to the ratios and particle sizes that matter more. Total cholesterol alone is a poor predictor of heart disease. What matters is the relationship between the numbers and the types of particles carrying the cholesterol. Small, dense LDL particles are far more dangerous than large, fluffy LDL particles, even if the total LDL number is the same. The triglyceride-to-HDL ratio is a better predictor of cardiovascular risk than LDL alone. And ApoB, a measure of the total number of atherogenic particles, is increasingly recognized as the single most important number on your lipid panel.

Beyond Cholesterol: The Metabolic Health Tests That Matter

Dr. Lustig expands the discussion beyond the standard lipid panel to include markers of insulin resistance and metabolic dysfunction. Fasting insulin, HOMA-IR, hemoglobin A1c, uric acid, and liver enzymes all provide information about your metabolic health that a basic cholesterol test misses. He argues, persuasively, that many people with "normal" cholesterol levels are still at high cardiovascular risk because of underlying insulin resistance and metabolic dysfunction that standard tests do not catch. This is relevant for the GLP-1 audience because these drugs primarily improve metabolic health, and tracking the right markers helps you see the full picture of how the medication is working.

The GLP-1 connection is straightforward: semaglutide and tirzepatide improve almost every marker Lustig discusses. They lower triglycerides, raise HDL, reduce small dense LDL particles, lower fasting insulin, improve HOMA-IR, reduce A1c, decrease liver enzymes (indicating reduced liver fat), and lower inflammatory markers like CRP. If you are on a GLP-1 drug and only tracking your weight, you are missing the bigger metabolic story. Your lab work may be improving in ways that reduce your cardiovascular risk far more than the number on the scale suggests. Dr. Lustig's framework gives you the tools to understand and track those improvements.

What the Video Gets Right

Dr. Lustig is one of the most effective science communicators in the metabolic health space. He explains complex biochemistry in terms that non-scientists can follow. His emphasis on triglyceride-to-HDL ratio and ApoB over total cholesterol and LDL is well-supported by current evidence and represents a more sophisticated understanding of cardiovascular risk than what most patients get from their doctors. His discussion of insulin resistance as the root cause of many cardiovascular risk factors is consistent with the metabolic health literature and provides a framework that makes GLP-1 drug benefits easier to understand.

What the Video Misses

The video is long and covers a lot of ground, which means some important topics get touched on only briefly. The practical question of how to get these tests ordered is addressed superficially. Many of the markers Lustig recommends (ApoB, fasting insulin, HOMA-IR, NMR particle size testing) are not included in standard lipid panels and may not be covered by insurance without specific justification. The video also does not explicitly connect the dots to GLP-1 medications, since it was not produced with that audience in mind. Viewers need to make the connection themselves between Lustig's metabolic health framework and the effects of the drugs they are taking. A section on how GLP-1 drugs affect each of these markers would make the video significantly more useful for that audience.

Questions to Bring to Your Doctor

Armed with the information from this video, you can ask your doctor for more detailed metabolic testing. Ask for an ApoB level if it is not already included in your lipid panel. Ask about NMR lipid particle testing, which distinguishes between small dense LDL and large buoyant LDL. Request a fasting insulin level and HOMA-IR calculation, more than fasting glucose. Ask about uric acid and liver enzymes as metabolic health indicators. If you are on a GLP-1 drug, ask your doctor to compare your pre-treatment labs with current results so you can see the full spectrum of metabolic improvement, more than weight change.

Building Your Personal Metabolic Dashboard

Dr. Lustig framework essentially encourages you to build a personal metabolic dashboard: a set of numbers that you track over time to understand your cardiometabolic health trajectory. Rather than fixating on a single number like total cholesterol or body weight, the dashboard approach gives you a multidimensional view of your health. Your dashboard might include fasting triglycerides, HDL cholesterol, triglyceride-to-HDL ratio, ApoB, fasting insulin, hemoglobin A1c, ALT and AST for liver function, CRP for inflammation, uric acid, and estimated GFR for kidney function. You do not need all of these at every blood draw, but tracking a core set of 5-6 markers every 3-6 months gives you a clear picture of whether your metabolic health is improving, stable, or declining.

For GLP-1 drug users specifically, this dashboard approach is powerful because it captures the full range of metabolic improvements that the medication produces. Many patients track only their weight, and while weight loss is the most visible change, it may not even be the most clinically important one. A patient who loses 20 pounds on semaglutide but whose triglycerides drop by 50%, CRP drops by 70%, and fasting insulin normalizes has achieved metabolic improvements that reduce their cardiovascular risk far more than the weight loss number alone would suggest. Conversely, a patient who loses weight but whose inflammatory markers remain elevated may need additional interventions beyond weight loss to address their cardiovascular risk fully. The dashboard tells you things that the scale cannot.

Creating this dashboard does not require expensive specialty testing. Most of the markers Lustig discusses are available through standard laboratory panels that are covered by insurance when ordered as part of a routine physical or chronic disease monitoring. ApoB and NMR lipid particle testing are the exceptions. They may require specific ordering and may not be covered by all plans. If your plan does not cover ApoB, the triglyceride-to-HDL ratio works as a reasonable proxy. If your doctor does not routinely order fasting insulin, you can request it and explain that you want to track insulin resistance alongside your lipid markers. Most doctors will agree to add these tests when a patient makes a specific, informed request.

The video also raises an important point about the limitations of standard reference ranges on lab reports. The reference range for fasting insulin, for example, typically goes up to about 25 microunits per milliliter, meaning a result of 24 would be flagged as normal. But optimal fasting insulin is probably below 10, and anything above 15 suggests meaningful insulin resistance. Similarly, a triglyceride level of 145 falls within the standard normal range but may indicate metabolic dysfunction when viewed in the context of your HDL level and other markers. Dr. Lustig encourages viewers to look beyond the normal/abnormal flags on their lab reports and to understand what the numbers actually mean in the context of their overall metabolic picture. This kind of health literacy is empowering and helps you have more productive conversations with your doctor about your treatment plan and your progress.

One final practical tip from Dr. Lustig framework: keep a personal health record that includes your lab results over time. Many electronic health record patient portals now allow you to download your lab results, but the presentation is often confusing and does not make it easy to see trends. Creating a simple spreadsheet that tracks your key metabolic markers over time, with dates, values, and any medication or lifestyle changes noted, gives you a powerful tool for visualizing your health trajectory and spotting trends that a single lab report cannot reveal. When you can show your doctor a chart demonstrating that your triglycerides dropped by 40% and your fasting insulin normalized over six months of GLP-1 treatment, that is a more compelling story than any single lab result viewed in isolation.

Who Should Watch This

Everyone who gets blood work done should watch this video. It transforms a confusing set of numbers into an understandable picture of your metabolic health. If you are on a GLP-1 drug, this video helps you understand the metabolic improvements that your medication is producing beyond weight loss. If you have been told your cholesterol is "fine" but you still have a family history of heart disease or metabolic risk factors, this video may prompt you to ask for more detailed testing. Healthcare providers will find Lustig's communication style useful as a model for explaining lab results to patients. The video is long, so set aside time to watch it in one sitting or break it into sections.

Understanding your lab work is one of the most empowering things you can do for your health. When you know what the numbers mean and how they connect to disease risk, you can have more productive conversations with your doctor, track your progress more accurately, and make better-informed decisions about your treatment plan.